Advancing PCOS Care
PCOS STAKEHOLDER MEETING
Developing Common Reference Ranges for Hormone Tests in Women and Adolescent Girls
WHEN
Monday, August 26, 2024
9:00 AM – 3:30 PM EDT
WHERE
Centers for Disease Control and Prevention (CDC)
Atlanta, GA, USA
Attend In-Person or Virtually
WHO
Organizer: PCOS Challenge:
The National Polycystic Ovary Syndrome Association
Host: CDC Clinical Standardization Programs
ABOUT THE PCOS STAKEHOLDER MEETING
Why should you attend the PCOS Stakeholder Meeting?
This important meeting will focus on developing standardized reference intervals (RI) for testosterone tests and potentially other biomarkers in women and adolescent girls. Attendees will gain insights into the latest research methodologies and collaborative efforts to harmonize testosterone measurement standards. This will help improve the accuracy of PCOS diagnosis and the reliability of clinical and research data, ultimately supporting better health outcomes for women and adolescent girls with PCOS.
``Delayed diagnosis of PCOS significantly impacts patient care, leading to prolonged periods with unaddressed symptoms and unmet health needs. Patients have consistently called for more accurate and timely diagnostic processes to improve their health outcomes. This meeting is a critical step towards addressing these urgent priorities by establishing standardized hormone reference intervals. By organizing this collaborative effort, we aim to enhance diagnostic precision and ensure that patients receive the appropriate care, reflecting our commitment to advancing the health of people with PCOS through innovation and evidence-based solutions.``
Sasha Ottey, MHA, MLS (ASCP) - Executive Director
MEETING GOALS
UNDERSTANDING
To provide clinical experts, researchers, and public health officials with a greater understanding of the importance of developing standardized reference intervals (RI) for testosterone tests in women and adolescent girls with PCOS. This will support more accurate diagnosis and effective management of PCOS.
CLARITY
Review and discuss existing study data and methodologies to identify the best approaches for normalizing and combining data to develop robust and broadly applicable RI for testosterone.
ACTIONABLE INSIGHTS
Establish technical and statistical procedures to derive standardized RI for testosterone, and explore the potential needs for additional biomarker data relevant to PCOS diagnosis and treatment.
Who Will Benefit From Attending the PCOS Stakeholder Meeting?
Clinical Experts
and
Researchers
Public Health Officials
Laboratory Standardization Experts
Healthcare Providers
Specializing in
Endocrinology and PCOS
FEATURED SPEAKERS
Sasha Ottey, MHA, MT (ASCP)
Executive Director
PCOS Challenge: The National Polycystic Ovary Syndrome Association
Hubert Vesper, PhD
Director, Clinical Standardization Programs
Centers for Disease Control and Prevention (CDC)
Andrea Dunaif, MD
System Chief
Hilda and J. Lester Gabrilove Division of Endocrinology, Diabetes and Bone Disease
Icahn School of Medicine at Mount Sinai Health System
Melanie Cree, MD, PhD
Associate Professor
University of Colorado Anschutz and Children’s Hospital Colorado
Alicia Lyle, PhD
Lead Research Chemist
Centers for Disease Control and Prevention (CDC)
Ricardo Azziz, MD, MPH, MBA
Christy Foster, MD
Assistant Professor
University of Alabama at Birmingham
Katherine Sherif, MD
Director
Jefferson Women’s Primary Care
Richard Auchus, MD, PhD
Professor, Endocrinology, Internal Medicine
Ann Arbor VA Medical Center
Jing Qian, PhD
Associate Professor of Biostatistics
Department of Biostatistics and Epidemiology
University of Massachusetts Amherst
ADVANCING PCOS CARE
Join us in establishing standardized reference intervals for testosterone tests, aiming to improve the diagnosis and treatment of polycystic ovary syndrome (PCOS).
STAY CONNECTED
For updates on PCOS and the Stakeholder Meeting to Develop Common Reference Ranges for Testosterone Tests, follow us on social media @PCOSChallenge.